Respiratory News and Research

RSS

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

Cord blood vitamin D linked to pediatric RTI risk

South Korean researchers say that encouraging pregnant women to spend more time outdoors or to increase their vitamin D supplementation may reduce the number of respiratory tract infections in their infants.

13 Jan 2014

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Research indicated that some Indigenous people such as in Alaska and Australia displayed limited immunity response to the effects of influenza.

13 Jan 2014

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

Meridian Bioscience, Inc. today announced that the company's TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens.

10 Jan 2014

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis.

10 Jan 2014

AOM associated with significant increases in direct costs incurred by consumers, health care system

Acute otitis media, or ear infection, is the most common ailment among kids of preschool age and younger in the U.S., primarily because these children have immature middle-ear drainage systems, higher exposure to respiratory illnesses and undeveloped immune systems.

10 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

ILiAD Biotechnologies, LLC, the French National Institute of Health and Medical Research subsidiary, Inserm Transfert SA, and Institut Pasteur de Lille today announced the signing of scientific collaboration and worldwide license agreements for live attenuated Bordetella pertussis vaccine technology, including BPZE1, developed by the laboratory of Professor Camille Locht. This license agreement covers patent rights from Institut Pasteur de Lille, Inserm, National University of Singapore and National University of Ireland Maynooth.

9 Jan 2014

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

The World health Organization calls depression "the leading cause of disability worldwide," causing more years of disability than cancer, HIV/AIDS, and cardiovascular and respiratory diseases combined.

8 Jan 2014

Forest Laboratories enters into definitive agreement to acquire Aptalis

Forest Laboratories, Inc. today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal and Cystic Fibrosis company, for $2.9 billion in cash from its shareholders, including TPG, the global private investment firm. The acquisition, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest's FY2015 non-GAAP EPS.

8 Jan 2014

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

Advanced Inhalation Therapies, an Israeli drug development company, announced today that it has begun enrollment in Israel for a multicenter, open label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis.

8 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Horizon Discovery and AstraZeneca have entered into a research, collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets. This deal is the second collaboration between AstraZeneca and Horizon, and follows the announcement in April 2013 of an oncology discovery program to explore Horizon's first-in-class kinase target program, HD-001.

7 Jan 2014

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice University's Baker Institute for Public Policy and the University of Texas MD Anderson Cancer Center.

7 Jan 2014

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Research from the National Institute of Respiratory Diseases informs that besides smoking, there are other factors associated to the development of lung cancer such as the smoke from burning lumber and coal, as well as pollutant particles.

7 Jan 2014

Clinical features not sufficiently pathognomonic in pneumonia

Clinical signs and symptoms are not sufficiently reliable to distinguish the different etiologies of pneumonia, Dutch researchers report.

6 Jan 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

People with severe mental illness may have higher risk for substance use

People with severe mental illness such as schizophrenia or bipolar disorder have a higher risk for substance use, especially cigarette smoking, and protective factors usually associated with lower rates of substance use do not exist in severe mental illness, according to a new study funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

5 Jan 2014

Study explores safety and efficacy of scoop and run approach in Philadelphia

A new study from the Perelman School of Medicine at the University of Pennsylvania has found no significant difference in adjusted overall survival rates between gunshot and stabbing (so-called penetrating trauma injuries) victims in Philadelphia whether they were transported to the emergency department by the police department or the emergency medical services division of the fire department.

3 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Respiratory News and Research

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

Cord blood vitamin D linked to pediatric RTI risk

Study indicates some groups have specific genetic make-up that prevents from fighting off influenza

Meridian's TRU FLU assay gets FDA clearance for analytical sensitivity claim for avian Influenza H7N9 strain

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

AOM associated with significant increases in direct costs incurred by consumers, health care system

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

ILiAD, Inserm and IPL sign worldwide license agreement for Bordetella pertussis vaccine technology

Hebrew University research could lead to efficient and fast-acting antidepressant drugs

Forest Laboratories enters into definitive agreement to acquire Aptalis

AIT initiates Phase II clinical trial of NOxCureCF for patients with cystic fibrosis

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Horizon, AstraZeneca partner to explore oncology-relevant genotypes to identify novel drug targets

Rice University, MD Anderson analyze complications on costs of complex cancer surgery

Researchers work on alternative therapy to boost immune system of patients with lung cancer

Clinical features not sufficiently pathognomonic in pneumonia

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

People with severe mental illness may have higher risk for substance use

Study explores safety and efficacy of scoop and run approach in Philadelphia

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News